Products

SOZO
ImpediMed Limited
Clinical Decision Support & Reference
SOZO by ImpediMed is a non-invasive bioimpedance spectroscopy (BIS) device designed for the early detection and ongoing management of lymphedema, providing rapid L-Dex scores and body composition analysis.

See all 1 product →

About ImpediMed

ImpediMed is a medical technology company specializing in non-invasive fluid and body composition assessment using Bioimpedance Spectroscopy (BIS) technology. Their flagship product, the SOZO® Digital Health Platform, is FDA-cleared, CE-marked, and ARTG-listed, offering clinicians a precise and rapid (under 30 seconds) method to monitor key health indicators. This technology is particularly valuable for the early detection and management of lymphedema, especially breast cancer-related lymphedema (BCRL), often identifying fluid changes before clinical symptoms manifest.

Beyond lymphedema, the SOZO platform extends its utility to other critical areas. It provides objective fluid status monitoring for patients with heart failure (HF-Dex™ analysis) and offers comprehensive body composition analysis (BodyComp Analysis), which is beneficial for medical weight management, wellness, and addressing protein calorie malnutrition. By generating thousands of unique data points, SOZO enables the creation of individualized baseline readings and facilitates longitudinal tracking, supporting personalized care across the patient journey. The cloud-connected platform seamlessly integrates into existing clinical workflows, providing real-time and historical data for both individual patient management and population-level trend analysis.

Focus Areas

Lymphedema detection and monitoring fluid status monitoring body composition analysis cancer survivorship heart health management medical weight management wellness

Business Intelligence

Key InvestorsParadice Investment Management, Australian Ethical Investments Ltd., Regal Funds Management, Starfish Ventures, Versant Ventures
PartnershipsAstraZeneca (clinical trials), Mayo Clinic (clinical trial agreement), Legacy Health
TechnologySOZO® Digital Health Platform, Bioimpedance Spectroscopy (BIS) technology, cloud-native, AI algorithms, L-Dex® Analysis, BodyComp™ Analysis, HF-Dex® Analysis
FDA Clearances5 cleared products (estimated)

What Physicians Need to Know

Lymphedema Detection & Monitoring
ImpediMed's SOZOu00ae Digital Health Platform, featuring L-Dexu00ae Analysis, is the only FDA-cleared Bioimpedance Spectroscopy (BIS) technology for the clinical assessment of lymphedema. It enables early detection of subclinical lymphedema (Stage 0) before visible swelling, allowing for timely intervention and potentially preventing progression to chronic conditions.
Fluid Status Monitoring
The SOZO platform non-invasively measures and monitors total body water, extracellular, and intracellular fluid volumes. This detailed data, including HF-Dexu2122 Analysis for heart failure, helps clinicians understand dynamic changes in fluid volume, providing a more complete picture of disease progression and treatment success, often before symptoms or significant weight changes occur.
Body Composition Analysis
Through BodyCompu2122 Analysis and Segmental BodyCompu2122 Analysis, ImpediMed provides comprehensive insights into fluid, muscle, and fat composition. It tracks changes in fat mass, fat-free mass, total body water, and skeletal muscle mass, aiding in clinical decisions and motivating patient compliance for improved outcomes.
Cancer Survivorship
The SOZO platform supports cancer survivorship by enabling proactive monitoring for lymphedema risk, a common side effect of cancer treatment. It also helps track changes in weight, muscle mass, bone health, and nutrition that can impact quality of life during and after cancer treatment.
Heart Health Management
ImpediMed's HF-Dexu2122 Analysis provides cardiologists with advanced body composition and fluid insights to gain a deeper, earlier understanding of patient status in heart failure. It helps identify fluid changes that may indicate increased risk of readmission, allowing for sooner intervention.
Medical Weight Management
The SOZO Digital Health Platform offers precision body composition assessment to monitor key health indicators for patients on medical weight management programs, including GLP-1 therapy. It tracks muscle preservation, fat loss, and validates fluid, fat mass, and muscle response to nutritional and exercise plans, moving beyond traditional BMI.
Wellness
ImpediMed's technology provides comprehensive fluid status and body composition analysis for general wellness and longevity. It helps monitor client response to wellness plans, including IV therapies, and offers insights into hydration and overall tissue composition.
Physician Tip

For physicians, ImpediMed's SOZO Digital Health Platform stands out due to its **FDA-cleared Bioimpedance Spectroscopy (BIS) technology**, which provides objective, non-invasive, and highly accurate measurements of fluid status and tissue composition. The ability to detect subclinical lymphedema with L-Dexu00ae and early fluid shifts in heart failure with HF-Dexu2122 allows for **proactive intervention**, potentially preventing chronic conditions and reducing hospitalizations. The platform is supported by **extensive clinical evidence**, including the PREVENT trial, and is recommended in national clinical practice guidelines (e.g., NCCN, NABPC). Its **ease of use** (30-second scan, performable by any care team member) and **immediate, cloud-connected results** streamline clinical workflow and enable comprehensive, personalized patient care. Furthermore, the availability of a **Category 1 CPT code (93702)** and growing reimbursement coverage from Medicare and private payers enhances patient access to this critical diagnostic tool.

The SOZO Digital Health Platform is designed for seamless integration into existing clinical workflows. Results are instantly available through the MySOZO web-based portal and can be integrated with Electronic Health Records (EHR) for auto-documentation. The system also offers integration into Active Directory and LDAP protocol for user account management.

Products by ImpediMed

1 product in the directory

SOZO
ImpediMed Limited
Clinical Decision Support & Reference
SOZO by ImpediMed is a non-invasive bioimpedance spectroscopy (BIS) device designed for the early detection and ongoing management of lymphedema, providing rapid L-Dex scores and body composition analysis.

What the Web Says

ImpediMed receives mixed reviews, with some users praising their L-Dex system for its effectiveness in lymphedema detection and ease of use, particularly in clinical settings. However, there are concerns regarding the company's internal culture, management, and compensation practices, as reflected in employer reviews. Product support is generally seen as adequate, but some wish for more comprehensive training.

Overall: Mixed

Strengths

  • L-Dex system is effective for lymphedema detection
  • Easy to use and integrate into clinical workflows
  • Provides objective data for patient management
  • Helpful for early intervention in lymphedema
  • Good for monitoring patient progress
  • Some users find the technology innovative

Limitations

  • Internal company culture issues reported by employees
  • Concerns about management and leadership decisions
  • Compensation and benefits may not be competitive
  • Limited career growth opportunities for some roles
  • Product training could be more comprehensive
  • Some reports of high employee turnover

Based on reviews from: Glassdoor, G2, Reddit, Capterra, Healthcare IT News (general industry sentiment)

Last updated: 2026-07-18

Videos

News, demos, and interviews about ImpediMed.

Loading videos...

Videos load interactively. If none appear, search YouTube for ImpediMed →

View all on YouTube

Press & Coverage

PR Newswire
ImpediMed Broadens Breast Cancer Survivorship Monitoring with the SOZOu00ae Digital Health Platform at ASBrS 2026
ImpediMed announced an expanded clinical vision for breast cancer survivorship care, showcasing its SOZO Digital Health Platform as an integrated fluid and body composition monitoring tool at the American Society of Breast Surgeons (ASBrS) 2026 Annual Meeting.
2026-05
ImpediMed
ImpediMed Appoints Erik Anderson as Chief Executive Officer
ImpediMed appointed Erik Anderson as its new Managing Director and CEO, effective April 7, 2026. Anderson previously joined the company's Board of Directors in February 2026.
2026-04
ImpediMed
ImpediMed Appoints Medical Technology Commercialization Expert Erik Anderson to Board of Directors
ImpediMed announced the appointment of Erik Anderson, a medical technology commercialization expert, to its Board of Directors. This appointment is expected to support the company's growth strategy and market expansion.
2026-02
PR Newswire
ImpediMed Secures $15m Growth Capital Funding
ImpediMed announced a five-year $15 million growth capital facility with SWK Holdings to fuel commercialization efforts for its lymphedema detection and monitoring platform technology.
2025-02
Stocks Down Under
ImpediMed (ASX:IPD) A$15.2m raise buys time for SOZO breakeven
ImpediMed successfully raised A$15.2 million through a A$13.2 million placement and a A$2 million share purchase plan, aiming to strengthen its balance sheet and support the commercialization of its SOZO platform in the US market.
2026-05
Kalkine
ImpediMed (ASX:IPD) Gains as After Reporting Encouraging Sales Momentum and Pipeline Growth
ImpediMed's shares rose following a CEO Business Update that highlighted encouraging unit sales momentum, expanding physician engagement, and growing interest in body composition applications for its SOZO platform.
2026-06
PR Newswire
New Guidance Published in The Lancet Recommends Early Intervention and Use of BIS to Reduce Impact of Arm Lymphedema on Breast Cancer Patients
New guidance published in The Lancet recommends early intervention and the use of Bioimpedance Spectroscopy (BIS) to reduce the impact of arm lymphedema on breast cancer patients.
2024-02
Therapeutic Goods Administration (TGA)
ImpediMed Ltd | Therapeutic Goods Administration (TGA)
The Australian Register of Therapeutic Goods (ARTG) lists ImpediMed Ltd's SOZO Pro as a body fat/lean ratio analyzer, with a listing date of May 1, 2024.
2024-05

Frequently Asked Questions

ImpediMed's SOZO Digital Health Platform, featuring L-Dex Analysis, is the only FDA-cleared Bioimpedance Spectroscopy (BIS) technology for the clinical assessment of lymphedema, especially in breast cancer-related cases. It non-invasively detects small, subclinical fluid changes in limbs, enabling early intervention to prevent progression to a chronic condition, as supported by the PREVENT trial and NCCN Guidelines.
The SOZO platform provides comprehensive fluid and tissue analysis, including extracellular and intracellular fluid volumes, fat mass, and lean mass, in under 30 seconds. This data is valuable for managing chronic conditions like heart failure (via HF-Dex Analysis), supporting medical weight management, and monitoring wellness and longevity across both healthy and unhealthy patient populations.
The SOZO Digital Health Platform is FDA-cleared, CE-marked, and ARTG listed, demonstrating compliance with international medical device regulations. It is also HITRUST CSFu00ae Certified and HIPAA-compliant, ensuring patient data stored in the cloud is encrypted both in-motion and at rest, providing robust security and privacy.
ImpediMed provides comprehensive customer and technical support, including resources like FAQs, IFU documents, and a Knowledge Center. They also offer clinical support specialists for installation, in-service education, and training on best practices for practice integration and product usage to ensure customer satisfaction.
ImpediMed operates on a subscription-based revenue model for its SOZO Digital Health Platform, providing recurring income. The company recently secured a five-year $15 million growth capital facility, indicating strong financial backing to support its commercialization strategy and long-term growth in expanding markets like cardiology, specialty medicine, and wellness.
Yes, SOZO's BIS testing has a Category 1 CPT code (93702) and is covered by Medicare and a growing number of national private payors in the U.S. ImpediMed provides complimentary reimbursement support to healthcare providers to help improve patient access to testing and ensure financial sustainability for practices.

Related Companies

QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]

Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.